Scholarships provide assistance to early-career physicians, scientists and researchers


Estimated Read Time:

5 minutes

Researchers from across the globe will participate and present their work during the 2020 SABCS Virtual Symposium with the help of scholarships awarded through SABCS and co-sponsor, the American Association for Cancer Research (AACR). Scholarships for attending SABCS have been awarded since before the turn of the century. The goal is to encourage and aid early-career researchers in getting their work seen and disseminated. Click here for details on scholarship requirements and eligibility.

Following are this year’s recipients, their topics and presentation times.


For laboratory-based investigators-in-training whose work focuses on the biology of breast cancer and preclinical models of its development and progression.

Zheqi Li, PhD, University of Pittsburgh; UPMC Hillman Cancer Center, Pittsburgh, PA
Hotspot ESR1 mutations rewire cell-cell adhesome to facilitate breast cancer metastasis
GS1-05 Wednesday, Dec. 9, 9:00 am

Amanda Fitzpatrick, Institute of Cancer Research, London, United Kingdom
Genomic profiling of breast cancer leptomeningeal metastasis (BCLM) reveals a divergent evolution and therapeutic targets
PD13-03 Friday, Dec. 11, 1:00 pm

Hitomi Mori, MD, Kyushu University, Fukuoka, Japan
Estrogen-induced cell cycle arrest as an unexpected outcome of aromatase inhibitor-resistance: Insights from single-cell trajectory analysis of a patient-derived xenograft model
PD7-02 Thursday, Dec. 10, 1:00 pm

Pooja Khanna, MS, Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ
Sox4 and smarca4 upregulate glycolysis-driven tumor proliferation through hexokinase 2 in tnbc
PD15-09 Friday, Dec. 11, 3:30 pm

Ran Li, FRACS, Peter MacCallum Cancer Centre, Melbourne, Australia
Tucatinib favourably modulates the immune microenvironment and synergises with anti-PD1 therapy in a trastuzumab resistant HER2+ murine model
PS10-04 Wednesday, Dec. 9


For clinical scientists-in-training who are actively pursuing clinical or clinical/ translational research in breast cancer.

Eva Blondeaux, MD, University of Genoa, Italy
Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis
GS3-09 Thursday, Dec. 10, 11:00 am

Biancastella Cereser, PhD, Imperial College London, London, United Kingdom
Mutational burden of the normal breast during age and pregnancy
PD5-10 Wednesday, Dec 9, 2:15 pm

Ali Raza Khaki, MD, University of Washington, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, WA
Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and Cancer Consortium (CCC19) Cohort Study
PS7-01 Wednesday, Dec. 9

Marieke van der Noordaa, MD, Netherlands Cancer Institute / University of California, BE, Amsterdam
Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore
GS4-07 Friday, Dec. 11, 10:15 am

Haiyun Wang, MD, MPH, Division of Hematology, Oncology and Transplanation, University of Minnesota Medical School, Minneapolis, MN
Impact of body mass index on pathological complete response after neoadjuvant chemotherapy: results from the I-SPY 2 Trial
PS6-05 Wednesday, Dec. 9


In memory of Dr. Charles A. Coltman, co-founder of SABCS, to commemorate the significant contributions he made to
oncology medicine. For clinical scientists-in-training.

Tim Robinson, MBBS, PhD, MRCP, University of Bristol, Bristol, United Kingdom
Exploring the causal role of the Human Gut Microbiome in Breast Cancer Risk using Mendelian Randomization
GS2-06 Wednesday, Dec. 9, 2:15 pm

Atul Batra, DM (Medical Oncology), Tom Baker Cancer Centre, University of Calgary, Calgary, Canada
Long-term risks of cerebrovascular accidents (CVAs) in patients with breast cancer
PD12-04 Friday, Dec. 11, 3:30 pm

Núria Chic Ruché, MD, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: a correlative analysis of neoALTTO trial
PS5-03 Wednesday, Dec. 9

Javier Pascual, MD, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom
Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: results from plasmaMATCH trial
PS5-02 Wednesday, Dec. 9

Kristine Gade, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
Patient reported outcomes and health care utilization of UPMC breast cancer survivorship clinic patients
PD12-10 Friday, Dec 11, 3:30 pm


For presenters of meritorious abstracts who are Associate Members of the American Association for Cancer Research (AACR).

Joyce V. Lee, PhD, University of California, San Francisco, San Francisco, CA
The MYC Oncogene Suppresses Tumor Immune Infiltration and Function which is Reversible with Combinatorial Immunotherapies
GS1-08 Wednesday, Dec. 9, 9:45 am

Yunan Han, MD, Washington University School of Medicine, St. Louis, MO
Changes in body mass index (BMI) over the life course are associated with gene expression in postmenopausal women
PS7-03 Wednesday, Dec. 9

Igor Makhlin, MD, University of Pennsylvania, Philadelphia, PA
Investigating the clinical utility of tumor mutational burden in predicting rapid progression and death in patients with metastatic breast cancer
PD9-10 Thursday, Dec. 10, 3:30 pm

Nawal Kassem, MD, Indiana University School of Medicine, Indianapolis, IN
Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recurrence: correlative analysis from clinical trial BRE12-158
PD15-06 Friday, Dec. 11, 3:30 pm

Hannah Grace Abraham, BSE, University of Michigan, Ann Arbor, MI
Incidence and survival of inflammatory breast cancer between 1973 – 2015 in the Surveillance, Epidemiology and End Results (SEER) database
PS7-06 Wednesday, Dec. 9

Sahil Seth, MS Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX
A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443)
PD9-05 Thursday, Dec. 10, 3:30 pm

Nour Abuhadra, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX
Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): molecular characteristics and outcomes with neoadjuvant therapy (NAT)
PS18-04 Wednesday, Dec. 9

Yun Lu, BSE, University of Alabama at Birmingham, Birmingham, AL
[89Zr]-pertuzumab pet imaging reveals paclitaxel treatment efficacy is positively correlated with her2 expression in human breast cancer xenograft mouse models
PS3-03 Wednesday, Dec. 9

Andrea Walens, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC
DNA repair imbalance and immune response in breast cancer mortality disparities
PS19-03 Wednesday, Dec. 9

Xuxu Gou, MS, Baylor College of Medicine, Houston, TX
Recurrent active ESR1 fusions render a diagnostic transcriptional signature in metastatic breast cancer
PS17-03 Wednesday, Dec. 9